B+
Bull case
0%
Probability
Target price
$145.00
Analysis reference price unavailable
Analysis 2026-07-17 · RankAlpha Sentiment Codex
MANE
VeradermicsDNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Positive VDPHL01 efficacy signals across male and female development programs, multiple second-half 2026 readouts, and stated runway into 2030 could support further clinical de-risking and eventual commercial optionality.
Posture
Defensive
Lead driver
Value
What changed
3 setup hits (3d) with net bullish as of 2026-10-25.
What can break
Clinical safety, tolerability, regulatory, enrollment, or launch execution could delay the program.
Momentum
98
Value
46
Sentiment
31
Setup hits (3d)
3 · Net Bullish
AI TargetsBase $105.00 · Bull $145.00 · Bear $72.00Analysis 2026-07-17; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-26 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-17 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-26
Investment thesis
As of 2026-10-26
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-26. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Bullish
Target $170.50
Why
Momentum98 · Δ7d -0.1
Value46 · Δ7d +0.0
Sentiment31 · Δ7d -21.6
So what
Weak posture (Net Bullish). Prioritize risk control and patience.
Confirming evidence
- • 3 setup hits (3d) with net bullish as of 2026-10-25.
- • Value remains the lead driver in the composite, 7D delta +0.0.
Contradictions & invalidation
- • Clinical safety, tolerability, regulatory, enrollment, or launch execution could delay the program.
- • Study 302 or Study 304 may fail to confirm topline efficacy or durability.
- • The current thesis remains dependent on future durability, confirmatory efficacy, safety, regulatory progress, and execution.
Catalyst clock
2026-10-15
Study 302 12-month data
Lead driver: Value · See fundamentals
Momentum
98
8% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
+2.4
Value
46
47% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
0.0
Sentiment
31
45% active weight
Current posture
7d trendSoftening
Δ7d
-21.6
Δ21d
-23.3
Why this grade
Composite grade D. Momentum 98.4 / Value 46.5 / Sentiment 31.4
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-07-17. Scenario method
Most likely
B
Base case
1%
Probability
Target price
$105.00
Analysis reference price unavailable
Analysis 2026-07-17 · RankAlpha Sentiment Codex
B-
Bear case
0%
Probability
Target price
$72.00
Analysis reference price unavailable
Analysis 2026-07-17 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$5.8B
Beta
-
Shares Out
41.78M
P/E (TTM) · Derived
-62.2
P/S (TTM)
-
P/FCF (TTM)
-
Rev YoY
-
EPS YoY
+16.6%
Gross Margin
-
Op Margin
-
Net Debt
-$141.86M
Current Ratio
70.53
As of 2026-10-26 • Updated nightlySource: Internal modelMethods & Data